GGrantIndex
← Search

Protocol Review and Monitoring System

$79,633P30FY2023CANIH

Wake Forest University Health Sciences, Winston-Salem NC

Investigators

Linked publications, trials & patents

Trial NCT07614022Trial NCT07324577Trial NCT07322367Trial NCT07282444Trial NCT07203534Trial NCT07196241Trial NCT07175376Trial NCT07119489Trial NCT07046936Trial NCT06945042Trial NCT06709404Trial NCT06654245Trial NCT06480591Trial NCT06441266Trial NCT06340503Trial NCT05984680Trial NCT05934851Trial NCT05877404Trial NCT05854966Trial NCT05825066Trial NCT05796518Trial NCT05696782Trial NCT05692635Trial NCT05597878Trial NCT05395936Trial NCT05309655Trial NCT05242770Trial NCT05212272Trial NCT05204290Trial NCT05030038Trial NCT04897217Trial NCT04858269Trial NCT04797884Trial NCT04677816Trial NCT04659993Trial NCT04623515Trial NCT04586127Trial NCT04526080Trial NCT04495751Trial NCT04485026Trial NCT04454489Trial NCT04430335Trial NCT04415944Trial NCT04375384Trial NCT04337580Trial NCT04327700Trial NCT04266470Trial NCT04253964Trial NCT04217317Trial NCT04174742Trial NCT04173247Trial NCT04111107Trial NCT04040244Trial NCT04037527Trial NCT03998189Trial NCT03987568Trial NCT03987555Trial NCT03982537Trial NCT03963739Trial NCT03958747Trial NCT03929211Trial NCT03890614Trial NCT03880526Trial NCT03874065Trial NCT03870529Trial NCT03870451Trial NCT03868943Trial NCT03867175Trial NCT03861091Trial NCT03861065Trial NCT03796273Trial NCT03746262Trial NCT03741868Trial NCT03741829Trial NCT03740035Trial NCT03681405Trial NCT03662074Trial NCT03529565Trial NCT03520283Trial NCT03505762Trial NCT03505736Trial NCT03505671Trial NCT03379376Trial NCT03374995Trial NCT03370159Trial NCT03188432Trial NCT03152786Trial NCT03148080Trial NCT03139435Trial NCT03122743Trial NCT03087591Trial NCT03032250Trial NCT02971410Trial NCT02971397Trial NCT02949843Trial NCT02835222Trial NCT02835066Trial NCT02832154Trial NCT02827838Trial NCT02747407

Abstract

PROTOCOL REVIEW AND MONITORING SYSTEM (PRMS): PROJECT SUMMARY The goal of the Protocol Review and Monitoring System (PRMS) is to provide independent peer review of the scientific merit, priority, feasibility, and progress of all clinical cancer research studies conducted within the Wake Forest Baptist Comprehensive Cancer Center (WFBCCC). The PRMS functions are accomplished by rigorous evaluations through a multi-stage review process conducted by: (1) WFBCCC’s multidisciplinary Disease- Oriented Teams (DOTs), where initial assessment of value, fit, and prioritization within the existing portfolio of studies is performed; (2) a Clinical Protocol and Data Management Feasibility Group (CPDM-FG), which reviews all operational considerations and/or logistical aspects of studies to ensure timely activation and completion; and (3) the Protocol Review Committee (PRC), which is the definitive independent authority for determining which studies proceed to activation based on scientific merit. The DOT approval and CPDM-FG’s review are required before proceeding to the PRC; however, only the PRC has final authority with regards to determining which studies will be activated. The PRMS process ensures that all WFBCCC clinical cancer research studies are: (1) scientifically sound; (2) effectively designed, specifically from a biostatistics perspective; (3) appropriately prioritized within the DOT’s research portfolio to avoid competing trials as well as align with WFBCCC’s overall institutional priorities for clinical research; (4) feasible for activation and completion (or in meeting institutional target accrual goals); (5) assessed for the adequacy of the data and safety monitoring plans based on the risk level of the study; and (6) monitored regularly for accrual and scientific progress. In 2020, the WFBCCC DOTs vetted in aggregate 185 studies and forwarded 112 of these studies to the CPDM-FG. Eighty-seven of these studies proceeded to PRC review. Once received by the PRC, 29 studies received an initial expedited review by a PRC Chair as they had already received an appropriate external scientific peer review, and 58 studies, primarily representing WFBCCC’s investigator-initiated and industry-sponsored trials, were forwarded for full PRC review. More than 28% (24/87) of the studies fully reviewed by the PRC required modifications prior to approval. None of the studies were disapproved. In addition, all studies were monitored for scientific and accrual progress, and 10 underperforming studies were closed in 2020. The PRMS, inclusive of the DOTs, CPDM-FG, and PRC review processes, is one of the most critical functions that the WFBCCC performs to ensure the highest quality of research is being conducted.

View original record on NIH RePORTER →